logo
logo
HomeAbout UsPlatformInsights

Merger & Acquisition

AllClinical TrialRegulatoryMerger & AcquisitionsBlogs
Deerfield bets up to $1.6B to snag autoimmune asset in China for BoulevardMergers and Acquisitions

01 Jul 2026

Deerfield bets up to $1.6B to snag autoimmune asset in China for Boulevard

Investment firm Deerfield Management, through its portfolio company Boulevard Bio, has licensed MTS-128, a trispecific T cell engager for autoimmune disease,...

Beeline ups its Series A round for immune drug workMergers and Acquisitions

01 Jul 2026

Beeline ups its Series A round for immune drug work

Beeline Medicines has secured an additional $126.3 million in its Series A funding round, bringing the total raised to $426.3 million. This substantial capital...

Ipsen to Acquire Kartos Therapeutics for Myelofibrosis DrugMergers and Acquisitions

01 Jul 2026

Ipsen to Acquire Kartos Therapeutics for Myelofibrosis Drug

French pharmaceutical company Ipsen is set to acquire California-based Kartos Therapeutics in a deal valued at $450 million upfront, with potential goal-based...

Novartis, Antares stars align in cancer deal that could top $1.9BMergers and Acquisitions

25 Jun 2026

Novartis, Antares stars align in cancer deal that could top $1.9B

Novartis and Antares Therapeutics have entered a collaboration to develop small molecule oncology therapies. Novartis will provide $105 million in upfront cash...

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in MexicoMergers and Acquisitions

25 Jun 2026

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

NurExone Biologic Inc.'s U.S. subsidiary, Exo-Top Inc., has entered a binding Memorandum of Understanding (MOU) with ExoLyra LLC for the exclusive distribution...

Big Pharma Restructures to Ride Out ‘Existential Risk’Mergers and Acquisitions

25 Jun 2026

Big Pharma Restructures to Ride Out ‘Existential Risk’

The pharmaceutical industry is facing an "existential risk" driven by a massive patent cliff, with an estimated $236 billion to $300 billion in market...

Serapha takes reverse merger route to Nasdaq with $230M and gene editor from ChinaMergers and Acquisitions

25 Jun 2026

Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China

Private biotech Serapha Bio is going public via a reverse merger with Boundless Bio, bringing $230 million in starting funds and a gene editing asset from...

UPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcyMergers and Acquisitions

24 Jun 2026

UPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy

Sangamo Therapeutics has filed for voluntary Chapter 11 bankruptcy, initiating a court-supervised reorganization and asset sale. The biotech is laying off 51...

Nuvectis, Haisco ink up to $1.4B deal for two late-stage programsMergers and Acquisitions

22 Jun 2026

Nuvectis, Haisco ink up to $1.4B deal for two late-stage programs

Nuvectis has in-licensed exclusive worldwide rights (excluding China, India, and specific Southeast Asia for NXP100) to two late-stage assets, NXP100 and...

Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and WalesMergers and Acquisitions

22 Jun 2026

Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales

Centessa Pharmaceuticals plc announced that the High Court of Justice of England and Wales has approved its proposed acquisition by Eli Lilly and Company. The...

Lilly bets up to $800M for BioArctic’s brain delivery techMergers and Acquisitions

22 Jun 2026

Lilly bets up to $800M for BioArctic’s brain delivery tech

Eli Lilly has entered into a research partnership with BioArctic to advance a novel, undisclosed drug candidate for an unnamed neurodegenerative disease. The...

AbbVie to Acquire Apogee, Staking Nearly $11B on Long-Acting Autoimmune DrugsMergers and Acquisitions

22 Jun 2026

AbbVie to Acquire Apogee, Staking Nearly $11B on Long-Acting Autoimmune Drugs

AbbVie announced its largest acquisition in years, agreeing to buy Apogee Therapeutics for nearly $11 billion to bolster its autoimmune disease portfolio. The...

Bionyra brings in $165M for next-generation immune drugsMergers and Acquisitions

22 Jun 2026

Bionyra brings in $165M for next-generation immune drugs

Bionyra, a biotechnology company co-founded by Sofinnova Partners and Frédéric Marrache, has emerged from stealth with $165 million in Series A funding. The...

Memento brings home $93M series A souvenir, picks up bispecific for eye diseasesMergers and Acquisitions

19 Jun 2026

Memento brings home $93M series A souvenir, picks up bispecific for eye diseases

Memento Medicines has successfully raised $93 million in Series A funding to advance its newly licensed lead asset, MMT-205, a bispecific antibody targeting...

New biotech cAMPfield emerges with $180M to reshape IBD treatmentMergers and Acquisitions

19 Jun 2026

New biotech cAMPfield emerges with $180M to reshape IBD treatment

cAMPfield Therapeutics has launched with $180 million in Series A funding to advance prifemilast, an oral PDE4 inhibitor, for inflammatory bowel disease (IBD)....

Biogen makes up to $1B immuno play with RayThera takeoverMergers and Acquisitions

19 Jun 2026

Biogen makes up to $1B immuno play with RayThera takeover

Biogen is set to acquire private biotech RayThera for up to $1 billion, significantly expanding its footprint in immunology. The deal, expected to close in the...

Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4BMergers and Acquisitions

18 Jun 2026

Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4B

Jazz Pharmaceuticals has entered into a collaboration with AbCellera to discover and develop next-generation T cell engagers for various gastrointestinal...

Amylyx Nears Regulatory Run in Obesity Surgery ComplicationMergers and Acquisitions

16 Jun 2026

Amylyx Nears Regulatory Run in Obesity Surgery Complication

Amylyx, following the market withdrawal of its ALS drug Relyvrio in March 2024 due to a Phase 3 trial failure, is strategically pivoting its pipeline. The...

GSK boosts cancer pipeline with $11B Nuvalent buyoutMergers and Acquisitions

10 Jun 2026

GSK boosts cancer pipeline with $11B Nuvalent buyout

GSK announced the acquisition of Massachusetts-based biotechnology company Nuvalent for $11 billion on June 9, 2026. This strategic move aims to bolster GSK's...

Stealthy startup Treeline plans a reverse mergerMergers and Acquisitions

10 Jun 2026

Stealthy startup Treeline plans a reverse merger

Treeline Biosciences, a secretive biotechnology firm, is going public through a reverse merger with microfluidics company Standard BioTools. The deal,...

Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.Mergers and Acquisitions

10 Jun 2026

Alembic Therapeutics, LLC Announces Acquisition of NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc.

Alembic Therapeutics, LLC has acquired NUVESSA® (metronidazole vaginal gel 1.3%) from Exeltis USA, Inc., an FDA-approved prescription medication for bacterial...

Roche makes up to $2.3B blood cancer play with Nurix’s protein degraderMergers and Acquisitions

09 Jun 2026

Roche makes up to $2.3B blood cancer play with Nurix’s protein degrader

Roche and Nurix Therapeutics have entered a deal worth up to $2.3 billion for the co-development and co-commercialization of bexobrutideg, an investigational...

J&J glows with $1B buyout of Firefly and its degrader platform techMergers and Acquisitions

09 Jun 2026

J&J glows with $1B buyout of Firefly and its degrader platform tech

Johnson & Johnson has acquired Firefly Bio for $1 billion in cash, securing its proprietary degrader antibody conjugate (DAC) platform technology. This...

Incyte to buy blood disorder drug in possibly $2B dealMergers and Acquisitions

09 Jun 2026

Incyte to buy blood disorder drug in possibly $2B deal

Incyte, a pharmaceutical company specializing in blood diseases and cancers, has announced its agreement to acquire Vega Therapeutics, a subsidiary of Star...

Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9BMergers and Acquisitions

04 Jun 2026

Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9B

Eli Lilly has entered into an RNA-focused alliance with Ascidian Therapeutics, involving an investment of up to $1.9 billion. This deal grants Lilly access to...

Travere beefs up rare kidney disease portfolio with up to $1.1B China dealMergers and Acquisitions

04 Jun 2026

Travere beefs up rare kidney disease portfolio with up to $1.1B China deal

Travere Therapeutics has entered into an exclusive global licensing agreement with Everest Medicines for civorebrutinib, an oral BTK inhibitor targeting rare...

Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy dealMergers and Acquisitions

02 Jun 2026

Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy deal

Servier is acquiring Edgewise Therapeutics' muscular dystrophy business for up to $2.65 billion, comprising a $1.55 billion upfront payment and $1.1 billion in...

Rallybio Attempts Second Reverse Merger with Avenzo TherapeuticsMergers and Acquisitions

02 Jun 2026

Rallybio Attempts Second Reverse Merger with Avenzo Therapeutics

Rallybio, a struggling drugmaker, has announced a second attempt at a reverse merger, this time with cancer drug developer Avenzo Therapeutics, following the...

Lilly maintains deal streak with $1.2B pact for Hanmi’s GLP-2 candidateMergers and Acquisitions

02 Jun 2026

Lilly maintains deal streak with $1.2B pact for Hanmi’s GLP-2 candidate

Eli Lilly has entered into a licensing agreement with South Korea’s Hanmi Pharm for sonefpeglutide, a mid-stage GLP-2 agonist being developed for short bowel...

Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s InnoventMergers and Acquisitions

29 May 2026

Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent

Pfizer has entered a significant strategic collaboration with China's Innovent Biologics to advance a pipeline of 12 novel antibody-based cancer therapies. The...

SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantumMergers and Acquisitions

29 May 2026

SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum

SciSparc Ltd. announced that its subsidiary, NeuroThera Labs Inc., received conditional regulatory approval from the TSX Venture Exchange for the acquisition...

Lilly dives into vaccine research with 3 biotech buyoutsMergers and Acquisitions

27 May 2026

Lilly dives into vaccine research with 3 biotech buyouts

Eli Lilly announced agreements to acquire three privately held vaccine developers—Vaccine Co., Curevo, and LimmaTech Biologics—for a combined value of up to...

Roche licensing pact clears generic drugmakers to manufacture antiviral flu drugMergers and Acquisitions

22 May 2026

Roche licensing pact clears generic drugmakers to manufacture antiviral flu drug

Roche has signed a voluntary license agreement with the Medicines Patent Pool (MPP), a United Nations–backed public health body, to allow generic manufacturers...

Oorja, run by Acceleron veterans, launches to make new fibrosis drugsMergers and Acquisitions

21 May 2026

Oorja, run by Acceleron veterans, launches to make new fibrosis drugs

Oorja Bio, a new biotechnology startup, has launched with $30 million in Series A funding from Westlake BioPartners. The Houston-based company announced plans...

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla BiotechMergers and Acquisitions

21 May 2026

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Jupiter Neurosciences, Inc. has entered into a term sheet to acquire exclusive, perpetual United States licensing rights for ALA-002, a lead drug candidate...

A migraine drugmaker heads to the public markets through reverse mergerMergers and Acquisitions

21 May 2026

A migraine drugmaker heads to the public markets through reverse merger

Mentari Therapeutics, a spinout from Paragon Therapeutics, is set to go public through a reverse merger with InMed Pharmaceuticals. The deal, announced on...

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)Mergers and Acquisitions

21 May 2026

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

Eton Pharmaceuticals has entered into a supply and distribution agreement with an affiliate of Knight Therapeutics, Inc. to acquire exclusive U.S....

Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3BMergers and Acquisitions

21 May 2026

Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B

Regeneron Pharmaceuticals has announced a significant partnership with Parabilis Medicines, committing up to $2.3 billion to create a new class of therapeutics...

Galapagos Rebrands as Lakefront Biotherapeutics After Strategic OverhaulMergers and Acquisitions

14 May 2026

Galapagos Rebrands as Lakefront Biotherapeutics After Strategic Overhaul

Galapagos, a Belgian biotech, has rebranded as Lakefront Biotherapeutics after 27 years, following a significant strategic overhaul. This transformation...

BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune dealMergers and Acquisitions

13 May 2026

BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal

Bristol Myers Squibb (BMS) and Hengrui Pharma have announced a strategic partnership to develop 13 investigational therapies for various cancers,...

Page 1 of 3Next →